Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 346

1.

Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.

Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML.

Antiviral Res. 2014 Nov;111:129-35. doi: 10.1016/j.antiviral.2014.09.005. Epub 2014 Sep 18.

2.

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG.

J Virol. 2010 Jan;84(2):1110-23. doi: 10.1128/JVI.01709-09. Epub 2009 Nov 4.

3.

Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.

Kim KH, Lee YT, Hwang HS, Kwon YM, Kim MC, Ko EJ, Lee JS, Lee Y, Kang SM.

J Virol. 2015 Nov;89(22):11692-705. doi: 10.1128/JVI.02018-15. Epub 2015 Sep 9.

4.

Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.

Hwang HS, Kim KH, Lee Y, Lee YT, Ko EJ, Park S, Lee JS, Lee BC, Kwon YM, Moore ML, Kang SM.

Hum Vaccin Immunother. 2017 May 4;13(5):1031-1039. doi: 10.1080/21645515.2016.1272743. Epub 2017 Jan 27.

5.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22. Epub 2007 Oct 10.

6.

Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.

Hwang HS, Lee YT, Kim KH, Park S, Kwon YM, Lee Y, Ko EJ, Jung YJ, Lee JS, Kim YJ, Lee YN, Kim MC, Cho M, Kang SM.

Virology. 2016 Jul;494:215-24. doi: 10.1016/j.virol.2016.04.014. Epub 2016 Apr 26.

7.

Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.

Cimica V, Boigard H, Bhatia B, Fallon JT, Alimova A, Gottlieb P, Galarza JM.

Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun.

8.

A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.

J Virol. 2017 May 12;91(11). pii: e00066-17. doi: 10.1128/JVI.00066-17. Print 2017 Jun 1.

9.

Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.

Qiao L, Zhang Y, Chai F, Tan Y, Huo C, Pan Z.

Antiviral Res. 2016 Jul;131:131-40. doi: 10.1016/j.antiviral.2016.05.001. Epub 2016 May 3.

PMID:
27154395
10.

A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.

Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang J, Hong T, He JS.

Antiviral Res. 2017 Aug;144:57-69. doi: 10.1016/j.antiviral.2017.05.005. Epub 2017 May 18.

PMID:
28529001
11.

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.

McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG.

J Virol. 2011 Jan;85(1):366-77. doi: 10.1128/JVI.01861-10. Epub 2010 Oct 27.

12.

Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW.

J Infect Dis. 2011 Oct 1;204(7):987-95. doi: 10.1093/infdis/jir474. Erratum in: J Infect Dis. 2012 Feb;205(3):520.

13.

Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.

Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG.

J Virol. 2014 Sep 1;88(17):10165-76. doi: 10.1128/JVI.01250-14. Epub 2014 Jun 25.

14.

Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.

Hwang HS, Kwon YM, Lee JS, Yoo SE, Lee YN, Ko EJ, Kim MC, Cho MK, Lee YT, Jung YJ, Lee JY, Li JD, Kang SM.

Antiviral Res. 2014 Oct;110:115-23. doi: 10.1016/j.antiviral.2014.07.016. Epub 2014 Aug 7.

15.

Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Lee JS, Kwon YM, Hwang HS, Lee YN, Ko EJ, Yoo SE, Kim MC, Kim KH, Cho MK, Lee YT, Lee YR, Quan FS, Kang SM.

Vaccine. 2014 Oct 7;32(44):5866-74. doi: 10.1016/j.vaccine.2014.08.045. Epub 2014 Aug 27.

16.

A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Wiegand MA, Gori-Savellini G, Gandolfo C, Papa G, Kaufmann C, Felder E, Ginori A, Disanto MG, Spina D, Cusi MG.

J Virol. 2017 Apr 28;91(10). pii: e02298-16. doi: 10.1128/JVI.02298-16. Print 2017 May 15.

17.

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.

Lee Y, Lee YT, Ko EJ, Kim KH, Hwang HS, Park S, Kwon YM, Kang SM.

Hum Vaccin Immunother. 2017 Nov 2;13(11):2594-2605. doi: 10.1080/21645515.2017.1362514.

18.

Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.

Phan SI, Zengel JR, Wei H, Li Z, Wang D, He B.

J Virol. 2017 Sep 12;91(19). pii: e00560-17. doi: 10.1128/JVI.00560-17. Print 2017 Oct 1.

19.
20.

Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.

Liang B, Munir S, Amaro-Carambot E, Surman S, Mackow N, Yang L, Buchholz UJ, Collins PL, Schaap-Nutt A.

J Virol. 2014 Apr;88(8):4237-50. doi: 10.1128/JVI.03481-13. Epub 2014 Jan 29.

Supplemental Content

Support Center